Please wait

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 10, 2025

graphic

STRATA SKIN SCIENCES, INC.
(Exact Name of Registrant Specified in Charter)

Delaware
000-51481
13-3986004
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania
 
19044
(Address of Principal Executive Offices)
 
(Zip Code)

Registrant's telephone number, including area code:   215-619-3200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
SSKN
The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



ITEM 5.07
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On December 10, 2025 the Company held its annual meeting of stockholders (the “Annual Meeting”).  The matters voted upon were:

(1) the election of five director nominees to the Company’s board of directors to serve until the next annual meeting of the Company’s stockholders or until their successors are elected and qualify, subject to their prior death, resignation or removal;

(2) to approve an amendment to our Amended and Restated 2016 Omnibus Incentive Plan (the “2016 Omnibus Incentive Plan”) to increase the number of shares of common stock reserved for issuance thereunder by 520,000 shares;

(3) to ratify the selection by the Audit Committee of the Board of Directors of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

The results of the voting were as follows:

(1) Each of the director nominees to the Company’s board of directors was elected:

Nominees
Votes For
Votes Withheld
Broker Non-Vote
Dr. Uri Geiger
2,208,832
46,203
1,010,399
Dr. Irit Yaniv
2,180,045
74,990
1,010,399
Christina Allgeier
2,180,415
74,620
1,010,399
Shmuel Rubinstein
2,225,313
29,718
1,010,399
Dr. Dolev Rafaeli
2,193,145
61,890
1,010,399

(2) to approve an amendment to the Company’s Amended and Restated 2016 Omnibus Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 520,000 shares

Votes For
Votes Against
Abstain
Broker Non-Vote
2,158,427
93,484
3,124
1,010,399

(3) to ratify the selection by the Audit Committee of the Board of Directors of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved

 
Votes For
Votes Against
Abstain
Broker Non-Vote
 
3,181,648
62,698
21,088
0

-2-

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
STRATA SKIN SCIENCES, INC.
 
       
Date: December 10, 2025
By:
/s/ John Gillings
 
   
John Gillings
 
   
Chief Accounting Officer
 


-3-